SCHEMBL469291

SCHEMBL469291

COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCC1(N(C)C)CC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.83
AXL P30530 8/20 0.83
KDR P35968 7/20 0.83
RET P07949 3/20 0.74
KIT P10721 3/20 0.74
FLT3 P36888 3/20 0.74
HDAC2 Q92769 2/20 0.74
HDAC8 Q9BY41 2/20 0.74
HDAC6 Q9UBN7 2/20 0.74
PDGFRB P09619 2/20 0.74
MERTK Q12866 5/20 0.73
HDAC10 Q969S8 1/20 0.72
HDAC11 Q96DB2 1/20 0.72
FLT1 P17948 3/20 0.69
AURKB Q96GD4 3/20 0.69
AURKA O14965 2/20 0.69
RIPK2 O43353 2/20 0.69
ABL1 P00519 2/20 0.69
EGFR P00533 2/20 0.69
ERBB2 P04626 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Exelixis SCHEMBL371899 0.91 MET (1.00) METAXLKDRRETKIT
Exelixis SCHEMBL29693473 0.91 MET (1.00) METAXLKDRRETKIT
SCHEMBL469347 0.90 MET (0.84) METAXLKDRRETKIT
SCHEMBL454493 0.89 MET (0.72) METAXLKDRRETKIT
SCHEMBL3233639 0.89 MET (0.82) METAXLKDRRETKIT
SCHEMBL24451294 0.88 MET (0.87) METAXLKDRRETKIT
SCHEMBL20096226 0.88 MET (0.87) METAXLKDRRETKIT
SCHEMBL15918448 0.88 MET (0.87) METAXLKDRRETKIT
SCHEMBL21847915 0.88 MET (0.81) METAXLKDRRETKIT
SCHEMBL21273565 0.88 MET (0.86) METAXLKDRRETKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621904-B1 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES LLC (US) 2020-04-22 EP disclosed
US-8664244-B2 Compounds as c-Met kinase inhibitors Advenchen Pharmaceuticals, LLC (US) 2014-03-04 US disclosed
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors CHEN GUOQING PAUL (US) 2012-05-17 US disclosed
WO-2012034055-A2 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES, LLC (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors MET, MERTK, HGF MET 1/4885AXL 75/4885KDR 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.